Evidence map›Paper›PMID 39473058›Full record

ArticleProteins2025

Selective Inhibition of hsp90 Paralogs: Uncovering the Role of Helix 1 in Grp94-Selective Ligand Binding.

Nanette L S Que, Paul M Seidler, Wen J Aw, Gabriela Chiosis, Daniel T Gewirth

Abstract read
In one paragraph

Article in Proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Conformational plasticity of a BiP-GRP94 chaperone complex.Nature structural & molecular biology · 2025
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Nanette L S QueHauptman Woodward Medical Research Institute, Buffalo, New York, USA.
Paul M SeidlerHauptman Woodward Medical Research Institute, Buffalo, New York, USA.
Wen J AwHauptman Woodward Medical Research Institute, Buffalo, New York, USA.
Gabriela ChiosisChemical Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Daniel T GewirthHauptman Woodward Medical Research Institute, Buffalo, New York, USA.ORCID 0000-0003-2702-3731

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Training and OutreachP30GM124166 · NIGMS · CORNELL UNIVERSITY · PI RICHARD A. CERIONE · 2019 to 2026
$28.3M
Project 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7M
National HTX Center: Enabling Access to State-of-the-Art Crystallization CapabilitiesR24GM141256 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Sarah Elizabeth Johnson Bowman · 2021 to 2026
$6.3M
Structure and Regulation of hsp90 ChaperonesR01CA095130 · NCI · HAUPTMAN-WOODWARD MEDICAL RESEARCH INST · PI GEWIRTH, DANIEL T · 2005 to 2015
$2.8M
N-glycosylation as a regulator of Grp94 Function and ActivityR01GM152842 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DANIEL T GEWIRTH · 2024 to 2026
$1.0M
Mae Stone Goode FoundationNCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA095130NIGMS NIH HHS P30 GM124166NIGMS NIH HHS R01 GM152842NIGMS NIH HHS R24 GM141256NIH HHS P01-CA186866NIH HHS R01-CA095130NIH HHS R01-GM152842NIH HHS R24GM141256
6 · The paper itself

Abstract

Grp94 is the endoplasmic reticulum paralog of the hsp90 family of chaperones, which have been targeted for therapeutic intervention via their highly conserved ATP binding sites. The design of paralog-selective inhibitors relies on understanding the protein structural elements that drive higher affinity in selective inhibitors. Here, we determined the structures of Grp94 and Hsp90 in complex with the Grp94-selective inhibitor PU-H36, and of Grp94 with the non-selective inhibitor PU-H71. In Grp94, PU-H36 derives its higher affinity by utilizing Site 2, a Grp94-specific side pocket adjoining the ATP binding cavity, but in Hsp90 PU-H36 occupies Site 1, a side pocket that is accessible in all paralogs with which it makes lower affinity interactions. The structure of Grp94 in complex with PU-H71 shows only Site 1 binding. While changes in the conformation of helices 4 and 5 in the N-terminal domain occur when ligands bind to Site 1 of both Hsp90 and Grp94, large conformational shifts that also involve helix 1 are associated with the engagement of the Site 2 pocket in Grp94 only. Site 2 in Hsp90 is blocked and its helix 1 conformation is insensitive to ligand binding. To understand the role of helix 1 in ligand selectivity, we tested the binding of PU-H36 and other Grp94-selective ligands to chimeric Grp94/Hsp90 constructs. These studies show that helix 1 is the major determinant of selectivity for Site 2 targeted ligands and also influences the rate of ATPase activity in Hsp90 paralogs.

Indexed as

HSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsMembrane GlycoproteinsAdenosine TriphosphateAnimalsBinding SitesCrystallography, X-RayHumansLigandsMembrane ProteinsModels, MolecularProtein BindingProtein Conformation, alpha-HelicalAdenosine Triphosphateendoplasminglucose-regulated proteinsHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsLigandsMembrane GlycoproteinsMembrane ProteinsATPaseGrp94Hsp90ITCparalog selectivityx‐ray crystallography

Identifiers

PMID39473058
PMCPMC11810606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.